A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of XH-S003 After Single Ascending Doses, Multiple Ascending Doses and Evaluation of Food Effects in Healthy Volunteers
Latest Information Update: 28 May 2025
At a glance
- Drugs XH S003 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors S-Infinity Pharmaceuticals
Most Recent Events
- 21 May 2025 Status changed from not yet recruiting to completed.
- 26 Feb 2024 New trial record